

# Product Information

**XPOVIO**<sup>®</sup>  
(selinexor)<sup>20 mg</sup>  
tablet

## INDICATIONS

- XPOVIO<sup>®</sup> (selinexor) in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody.
- XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.

These indications are approved under accelerated approval based on response rate. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

## DISTRIBUTION

XPOVIO can be accessed through the following authorized specialty pharmacies and specialty distributors:

### Authorized Specialty Pharmacies

|                                  |                |                        |                    |
|----------------------------------|----------------|------------------------|--------------------|
| <b>Biologics</b>                 | 1.800.850.4306 | biologics.mckesson.com | Fax 1.800.823.4506 |
| <b>Onco360 Oncology Pharmacy</b> | 1.877.662.6633 | onco360.com            | Fax 1.877.662.6355 |
| <b>US Bioservices</b>            | 1.877.757.0667 | usbioservices.com      | Fax 1.888.899.0067 |

### Authorized Specialty Distributors

|                                               |                |                                    |
|-----------------------------------------------|----------------|------------------------------------|
| <b>ASD Healthcare</b>                         | 1.800.746.6273 | asdhealthcare.com                  |
| <b>Cardinal Health Specialty Distribution</b> | 1.866.677.4844 | specialtyonline.cardinalhealth.com |
| <b>McKesson Plasma &amp; Biologics</b>        | 1.877.625.2566 | connect.mckesson.com               |
| <b>McKesson Specialty</b>                     | 1.800.482.6700 | mscs.mckesson.com                  |
| <b>Oncology Supply</b>                        | 1.800.633.7555 | oncologysupply.com                 |

Contact an XPOVIO field representative at [XPOVIOpro.com](http://XPOVIOpro.com)



**A patient support program by Karyopharm dedicated to providing assistance and resources to patients and their caregivers for XPOVIO<sup>®</sup> (selinexor) treatment.**

KaryForward can assist with:



**Insurance Coverage**



**Financial Assistance**



**Support and Resources**

To learn more, call 1-877-KARY4WD (1-877-527-9493), Monday through Friday, 8am-8pm ET or visit [KaryForward.com](http://KaryForward.com).

**Please see full [Prescribing Information](#).**

For medical information, to report an adverse event or product complaint, please call: 1-888-209-9326 or email: [medicalinformation@karyopharm.com](mailto:medicalinformation@karyopharm.com).

© 2020 Karyopharm Therapeutics Inc. All rights reserved. US-XPOV-12/18-00037 (06/20)



# Product Information

(cont'd)



## HOW SUPPLIED

XPOVIO are blue, round, bi-convex, and film-coated 20 mg tablets with “K20” debossed on one side and nothing on the other side. Tablets are packaged in a child-resistant blister pack. Four blister packs are supplied per carton.

### For RRMM

| NDC                     | Contents                                         | Tablets per Blister Pack | Weekly Dose           | Carton |
|-------------------------|--------------------------------------------------|--------------------------|-----------------------|--------|
| <u>NDC 72237-101-04</u> | 4 blister packs<br>(32 tablets total per carton) | Eight<br>20-mg tablets   | 80 mg<br>twice weekly |        |
| <u>NDC 72237-101-05</u> | 4 blister packs<br>(20 tablets total per carton) | Five<br>20-mg tablets    | 100 mg<br>once weekly |        |
| <u>NDC 72237-101-02</u> | 4 blister packs<br>(16 tablets total per carton) | Four<br>20-mg tablets    | 80 mg<br>once weekly  |        |
| <u>NDC 72237-101-01</u> | 4 blister packs<br>(12 tablets total per carton) | Three<br>20-mg tablets   | 60 mg<br>once weekly  |        |

### For RR DLBCL

| NDC                     | Contents                                         | Tablets per Blister Pack | Weekly Dose           | Carton |
|-------------------------|--------------------------------------------------|--------------------------|-----------------------|--------|
| <u>NDC 72237-101-03</u> | 4 blister packs<br>(24 tablets total per carton) | Six<br>20-mg tablets     | 60 mg<br>twice weekly |        |
| <u>NDC 72237-101-06</u> | 4 blister packs<br>(16 tablets total per carton) | Four<br>20-mg tablets    | 40 mg<br>twice weekly |        |
| <u>NDC 72237-101-01</u> | 4 blister packs<br>(12 tablets total per carton) | Three<br>20-mg tablets   | 60 mg<br>once weekly  |        |
| <u>NDC 72237-101-07</u> | 4 blister packs<br>(8 tablets total per carton)  | Two<br>20-mg tablets     | 40 mg<br>once weekly  |        |

## STORAGE

- Store at or below 30°C (86°F).

Please see full [Prescribing Information](#).

For medical information, to report an adverse event or product complaint, please call: 1-888-209-9326 or email: [medicalinformation@karyopharm.com](mailto:medicalinformation@karyopharm.com).

© 2020 Karyopharm Therapeutics Inc. All rights reserved. US-XPOV-12/18-00037 (06/20)

